NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Black Diamond Therapeutics, Inc. BDTX
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$70.0M
EPS · FY25
$0.39
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
22.9%
Net margin · FY25
32.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 70.0M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
32 cents of every revenue dollar became profit this year.
Per share
USD 0.39
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
22.9%
Return on equity, FY2025
ROE
Operating margin17.9%
Net margin32.0%
Return on assets16.8%
Each USD of equity produced 23 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+58.4%
Change, 10 years—
The share count grew 58% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 143.0M
total assets, end of FY2025
Total assetsUSD 143.0M
EquityUSD 112.2M
CashUSD 21.0M
Current ratio8.42×
Equity funds 78% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.1
0.0
·
·
·
0.0
0.0
0.0
Operating income $B
0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
0.39
−1.27
−1.88
−2.52
−3.47
−2.05
−16.99
−4.42
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
22.9
−69.7
−70.9
−58.5
−49.9
−51.6
·
·
Shares out B
0.06
0.06
0.05
0.04
0.04
0.04
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed